Literature DB >> 21281813

Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Kunie Ando1, Karelle Leroy, Céline Héraud, Zehra Yilmaz, Michèle Authelet, Valèrie Suain, Robert De Decker, Jean-Pierre Brion.   

Abstract

Many models of human tauopathies have been generated in mice by expression of a human mutant tau with maintained expression of mouse endogenous tau. Because murine tau might interfere with the toxic effects of human mutant tau, we generated a model in which a pathogenic human tau protein is expressed in the absence of wild-type tau protein, with the aim of facilitating the study of the pathogenic role of the mutant tau and to reproduce more faithfully a human tauopathy. The Tg30 line is a tau transgenic mouse model overexpressing human 1N4R double-mutant tau (P301S and G272V) that develops Alzheimer's disease-like neurofibrillary tangles in an age-dependent manner. By crossing Tg30 mice with mice invalidated for their endogenous tau gene, we obtained Tg30xtau(-/-) mice that express only exogenous human double-mutant 1N4R tau. Although Tg30xtau(-/-) mice express less tau protein compared with Tg30, they exhibit signs of decreased survival, increased proportion of sarkosyl-insoluble tau in the brain and in the spinal cord, increased number of Gallyas-positive neurofibrillary tangles in the hippocampus, increased number of inclusions in the spinal cord, and a more severe motor phenotype. Deletion of murine tau accelerated tau aggregation during aging of this mutant tau transgenic model, suggesting that murine tau could interfere with the development of tau pathology in transgenic models of human tauopathies.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281813      PMCID: PMC3069830          DOI: 10.1016/j.ajpath.2010.10.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  75 in total

1.  The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies.

Authors:  D P Hanger; G M Gibb; R de Silva; A Boutajangout; J-P Brion; T Revesz; A J Lees; B H Anderton
Journal:  FEBS Lett       Date:  2002-11-20       Impact factor: 4.124

2.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

3.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.

Authors:  T Ishihara; B Zhang; M Higuchi; Y Yoshiyama; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Authors:  Bridget Allen; Esther Ingram; Masaki Takao; Michael J Smith; Ross Jakes; Kanwar Virdee; Hirotaka Yoshida; Max Holzer; Molly Craxton; Piers C Emson; Cristiana Atzori; Antonio Migheli; R Anthony Crowther; Bernardino Ghetti; Maria Grazia Spillantini; Michel Goedert
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

5.  Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.

Authors:  Naruhiko Sahara; Jada Lewis; Michael DeTure; Eileen McGowan; Dennis W Dickson; Mike Hutton; Shu-Hui Yen
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

6.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

7.  Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

Authors:  Makoto Higuchi; Takeshi Ishihara; Bin Zhang; Ming Hong; Athena Andreadis; John Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-08-01       Impact factor: 17.173

8.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

Authors:  Cathy Andorfer; Yvonne Kress; Marisol Espinoza; Rohan de Silva; Kerry L Tucker; Yves-Alain Barde; Karen Duff; Peter Davies
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

9.  Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.

Authors:  T Chris Gamblin; Feng Chen; Angara Zambrano; Aida Abraha; Sarita Lagalwar; Angela L Guillozet; Meiling Lu; Yifan Fu; Francisco Garcia-Sierra; Nichole LaPointe; Richard Miller; Robert W Berry; Lester I Binder; Vincent L Cryns
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

10.  Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration.

Authors:  Yih-Cherng Liou; Anyang Sun; Akihide Ryo; Xiao Zhen Zhou; Zhao-Xue Yu; Han-Kuei Huang; Takafumi Uchida; Roderick Bronson; Guoying Bing; Xiaojiang Li; Tony Hunter; Kun Ping Lu
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

View more
  26 in total

1.  Dorsal root ganglion neurons carrying a P301S Tau mutation: a valid in vitro model for screening drugs against tauopathies?

Authors:  Niels Alberts; Karlijn Groen; Lisette Klein; Marek J Konieczny; Mandy Koopman
Journal:  J Neurosci       Date:  2014-04-02       Impact factor: 6.167

2.  Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications.

Authors:  Se Hoon Choi; Young Hye Kim; Carla D'Avanzo; Jenna Aronson; Rudolph E Tanzi; Doo Yeon Kim
Journal:  US Neurol       Date:  2015

3.  Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice.

Authors:  Noah R Johnson; Carlo Condello; Shenheng Guan; Abby Oehler; Julia Becker; Marta Gavidia; George A Carlson; Kurt Giles; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

4.  Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent.

Authors:  Miranda E Orr; Valentina R Garbarino; Angelica Salinas; Rochelle Buffenstein
Journal:  Neurobiol Aging       Date:  2014-12-12       Impact factor: 4.673

5.  Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.

Authors:  Emily J Koller; Elsa Gonzalez De La Cruz; Timothy Machula; Kristen R Ibanez; Wen-Lang Lin; Tosha Williams; Cara J Riffe; Daniel Ryu; Kevin H Strang; Xuefei Liu; Christopher Janus; Todd E Golde; Dennis Dickson; Benoit I Giasson; Paramita Chakrabarty
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

6.  Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.

Authors:  Raphaëlle Caillierez; Séverine Bégard; Katia Lécolle; Vincent Deramecourt; Nadège Zommer; Simon Dujardin; Anne Loyens; Noëlle Dufour; Gwennaëlle Aurégan; Joris Winderickx; Philippe Hantraye; Nicole Déglon; Luc Buée; Morvane Colin
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

Review 7.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

8.  Lessons from tau-deficient mice.

Authors:  Yazi D Ke; Alexandra K Suchowerska; Julia van der Hoven; Dineeka M De Silva; Christopher W Wu; Janet van Eersel; Arne Ittner; Lars M Ittner
Journal:  Int J Alzheimers Dis       Date:  2012-06-06

9.  Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase.

Authors:  Hervé Maurin; Benoit Lechat; Ilse Dewachter; Laurence Ris; Justin V Louis; Peter Borghgraef; Herman Devijver; Tomasz Jaworski; Fred Van Leuven
Journal:  Mol Brain       Date:  2013-05-25       Impact factor: 4.041

10.  A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.

Authors:  Gianmario Ciaccioli; Ana Martins; Cátia Rodrigues; Helena Vieira; Patrícia Calado
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.